Logo

BMS Reports EMA's Validation of MAA for Idecabtagene Vicleucel (Ide-cel- bb2121) and CC-486

Share this

BMS Reports EMA's Validation of MAA for Idecabtagene Vicleucel (Ide-cel- bb2121) and CC-486

Shots:

  • The MAA of ide-cel is based on P-II KarMMa study assessing ide-cel in heavily pre-treated 140 patients with r/r MM- prior treated with at least 3 therapies including an immunomodulatory agent- a proteasome inhibitor and an anti-CD38 antibody
  • The MAA of CC-486 is based on P-III QUAZAR AML-001 study assessing CC-486 (300mg) vs PBO in 472 patients in a ratio (1:1) with AML- who CR/ CRi- following induction therapy with/out consolidation treatment- and who are not candidates for hematopoietic stem cell transplantation
  • Ide-cel is BCMA directed genetically modified autologous CART cell immunotherapy- co-developed by BMS and bluebird- and has received EMA’s Accelerated Assessment status in Mar 26- 2020- reducing the maximum timeframe for review of the application to 150 days. CC-486 is an oral hypomethylating agent that incorporates into DNA and RNA

Click here ­to­ read full press release/ article 

Ref: BMS | Image: BMS

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions